Zacks Investment Research upgraded shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) from a hold rating to a buy rating in a research note issued to investors on Saturday morning. The brokerage currently has $0.75 price objective on the biotechnology company’s stock.
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
Several other research analysts have also issued reports on the stock. Chardan Capital reduced their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a buy rating on the stock in a research note on Tuesday, August 8th. Maxim Group reaffirmed a hold rating on shares of Ritter Pharmaceuticals in a research note on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $4.88.
Shares of Ritter Pharmaceuticals (RTTR) opened at 0.557 on Friday. Ritter Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.75. The firm’s market capitalization is $8.22 million. The company’s 50-day moving average is $0.57 and its 200 day moving average is $1.05.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). On average, analysts expect that Ritter Pharmaceuticals will post ($0.42) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Ritter Pharmaceuticals, Inc. (RTTR) Lifted to “Buy” at Zacks Investment Research” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/09/12/ritter-pharmaceuticals-inc-rttr-lifted-to-buy-at-zacks-investment-research.html.
An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. grew its holdings in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the quarter. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period. Institutional investors own 7.62% of the company’s stock.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.